$62.8
+0.68
(+1.09%)β²
Insights on Bio-techne Corp.
Revenue is down for the last 3 quarters, 301.32M β 272.59M (in $), with an average decrease of 4.8% per quarter
Netprofit is down for the last 3 quarters, 75.48M β 27.46M (in $), with an average decrease of 39.3% per quarter
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 69.9%
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 280.2%
1.57%
Downside
Day's Volatility :2.46%
Upside
0.91%
17.95%
Downside
52 Weeks Volatility :42.34%
Upside
29.73%
Period | Bio-techne Corp. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -13.36% | -0.4% | 3.0% |
6 Months | -0.96% | 9.6% | 18.8% |
1 Year | -25.33% | 3.9% | 21.2% |
3 Years | -41.92% | 12.8% | 19.9% |
Market Capitalization | 9.8B |
Book Value | $12.5 |
Dividend Share | 0.32 |
Dividend Yield | 0.52% |
Earnings Per Share (EPS) | 1.39 |
PE Ratio | 44.69 |
PEG Ratio | 1.15 |
Wall Street Target Price | 80.55 |
Profit Margin | 19.58% |
Operating Margin TTM | 18.39% |
Return On Assets TTM | 6.32% |
Return On Equity TTM | 11.83% |
Revenue TTM | 1.1B |
Revenue Per Share TTM | 7.26 |
Quarterly Revenue Growth YOY | 0.4% |
Gross Profit TTM | 770.2M |
EBITDA | 323.4M |
Diluted Eps TTM | 1.39 |
Quarterly Earnings Growth YOY | -0.45 |
EPS Estimate Current Year | 1.77 |
EPS Estimate Next Year | 2.04 |
EPS Estimate Current Quarter | 0.41 |
EPS Estimate Next Quarter | 0.49 |
What analysts predicted
Upside of 28.26%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 643.0M | β 14.21% |
Net Income | 125.4M | β 62.19% |
Net Profit Margin | 19.49% | β 5.76% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 714.0M | β 11.04% |
Net Income | 96.1M | β 23.36% |
Net Profit Margin | 13.46% | β 6.03% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 738.7M | β 3.46% |
Net Income | 229.3M | β 138.67% |
Net Profit Margin | 31.04% | β 17.58% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 931.0M | β 26.04% |
Net Income | 140.4M | β 38.76% |
Net Profit Margin | 15.08% | β 15.96% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | β 18.75% |
Net Income | 272.1M | β 93.75% |
Net Profit Margin | 24.61% | β 9.53% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | β 2.81% |
Net Income | 285.3M | β 4.86% |
Net Profit Margin | 25.1% | β 0.49% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 269.7M | β 6.44% |
Net Income | 89.6M | β 45.56% |
Net Profit Margin | 33.21% | β 11.86% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 271.6M | β 0.71% |
Net Income | 50.0M | β 44.16% |
Net Profit Margin | 18.41% | β 14.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 294.1M | β 8.31% |
Net Income | 70.2M | β 40.42% |
Net Profit Margin | 23.87% | β 5.46% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 301.3M | β 2.44% |
Net Income | 75.5M | β 7.5% |
Net Profit Margin | 25.05% | β 1.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 276.9M | β 8.09% |
Net Income | 51.0M | β 32.45% |
Net Profit Margin | 18.41% | β 6.64% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 272.6M | β 1.57% |
Net Income | 27.5M | β 46.14% |
Net Profit Margin | 10.08% | β 8.33% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | β 2.35% |
Total Liabilities | 514.1M | β 15.15% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | β 18.28% |
Total Liabilities | 718.8M | β 39.83% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | β 7.6% |
Total Liabilities | 646.4M | β 10.08% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | β 11.61% |
Total Liabilities | 691.7M | β 7.01% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | β 1.41% |
Total Liabilities | 593.8M | β 14.16% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.6B | β 14.99% |
Total Liabilities | 672.2M | β 13.2% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.4B | β 2.44% |
Total Liabilities | 599.6M | β 0.97% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.4B | β 0.54% |
Total Liabilities | 536.3M | β 10.55% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | β 10.0% |
Total Liabilities | 710.0M | β 32.39% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | β 1.5% |
Total Liabilities | 672.2M | β 5.33% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.8B | β 4.42% |
Total Liabilities | 757.6M | β 12.71% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | β 0.89% |
Total Liabilities | 767.2M | β 1.26% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 170.4M | β 18.77% |
Investing Cash Flow | -38.7M | β 87.35% |
Financing Cash Flow | -99.2M | β 152.37% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 181.6M | β 6.6% |
Investing Cash Flow | -336.8M | β 770.01% |
Financing Cash Flow | 134.4M | β 235.48% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 205.2M | β 12.99% |
Investing Cash Flow | 27.1M | β 108.04% |
Financing Cash Flow | -183.8M | β 236.77% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 352.2M | β 71.61% |
Investing Cash Flow | -243.5M | β 998.75% |
Financing Cash Flow | -62.6M | β 65.97% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 325.3M | β 7.64% |
Investing Cash Flow | -96.9M | β 60.23% |
Financing Cash Flow | -242.9M | β 288.25% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 254.4M | β 21.79% |
Investing Cash Flow | -265.6M | β 174.29% |
Financing Cash Flow | 22.6M | β 109.31% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 56.1M | β 45.4% |
Investing Cash Flow | -19.7M | β 6.02% |
Financing Cash Flow | -31.8M | β 51.61% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 64.4M | β 14.81% |
Investing Cash Flow | -109.0K | β 99.45% |
Financing Cash Flow | -72.2M | β 126.99% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 50.5M | β 21.51% |
Investing Cash Flow | -241.1M | β 221088.99% |
Financing Cash Flow | 150.8M | β 308.93% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 83.4M | β 65.02% |
Investing Cash Flow | -4.8M | β 98.03% |
Financing Cash Flow | -24.2M | β 116.06% |
Sell
Neutral
Buy
Bio-techne Corp. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Bio-techne Corp. | -9.27% | -0.96% | -25.33% | -41.92% | 30.89% |
Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Bio-techne Corp. | 44.69 | 44.69 | 1.15 | 1.77 | 0.12 | 0.06 | 0.01 | 12.5 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Bio-techne Corp. | Buy | $9.8B | 30.89% | 44.69 | 19.58% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Vanguard Group Inc
BlackRock Inc
State Street Corporation
BAMCO Inc
Select Equity Group LP
Morgan Stanley - Brokerage Accounts
In the quarter ending March,2024. Bio-techne Corp. has declared dividend of $0.08
Read Morebio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.
Organization | Bio-techne Corp. |
Employees | 3200 |
CEO | Mr. Kim Kelderman |
Industry | Health Technology |
Cg Oncology Inc.
$62.80
+1.09%
Taiwan Msci Etf Ishares
$62.80
+1.09%
Sl Green Realty Corp.
$62.80
+1.09%
Lg Display Co., Ltd.
$62.80
+1.09%
Willscot Mobile Mini Holding
$62.80
+1.09%
Nnn Reit Inc.
$62.80
+1.09%
Cerevel Therapeutics Holdings Inc
$62.80
+1.09%
Spdr S&p 400 Mid Cap Value E
$62.80
+1.09%
Vanguard Russell 1000 Etf
$62.80
+1.09%